Management of complications of androgen deprivation therapy in the older man

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 3, 2009, Pages 235-255

  Mohile, Supriya G ^a   Mustian, Karen ^a   Bylow, Kathryn ^b   Hall, William ^a   Dale, William ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Androgen deprivation; Complications; Disability; Functional impairment; Geriatric assessment; Prostate cancer; Quality of life; Vulnerable elders

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANTIANDROGEN; ANTIDEPRESSANT AGENT; BICALUTAMIDE; CALCIUM; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GABAPENTIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NILUTAMIDE; PAMIDRONIC ACID; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SERTRALINE; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ACUPUNCTURE; AGING; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER PATIENT; CASTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DRUG DOSE TITRATION; DRUG INHIBITION; DRUG INTERMITTENT THERAPY; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FRACTURE; GYNECOMASTIA; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HOT FLUSH; HUMAN; KIDNEY FAILURE; LIBIDO DISORDER; MAJOR DEPRESSION; MALE SEXUAL DYSFUNCTION; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; MOOD; MUSCLE ATROPHY; NIPPLE MALFORMATION; OSTEOPENIA; OSTEOPOROSIS; PATIENT COUNSELING; PENIS NOCTURNAL TUMESCENCE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SODIUM RETENTION; STROKE; SUDDEN DEATH; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; HOT FLASHES; HUMANS; MALE; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 67349141307     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.004     Document Type: Review

References (189)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
2. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 11 6 (2005) 437-441
3. Crawford E.D. Epidemiology of prostate cancer. Urology 62 6 Suppl. 1 (2003) 3-12
4. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 11 (2004) 2141-2149
5. Lu-Yao G., Stukel T.A., and Yao S.L. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 171 6 Pt 1 (2004) 2285-2290
6. Newschaffer C.J., Otani K., McDonald M.K., and Penberthy L.T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92 8 (2000) 613-621
7. Gatling R.R. Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. South Med J 83 7 (1990) 782-784
8. Konety B.R., Bird V.Y., Deorah S., and Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 174 5 (2005) 1785-1788 discussion 8
9. Brawer M.K., Crawford E.D., Fowler J., Lucia M.S., and Schroeder F.H. Prostate cancer: epidemiology and screening. Rev Urol 2 Suppl 4 (2000) S5-S9
10. Balducci L., and Aapro M. Epidemiology of cancer and aging. Cancer Treat Res 124 (2005) 1-15
11. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 12 (2007) 1596-1605
12. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 21 4 (2003) 245-254
13. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., and Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 8 (2005) 1615-1624
14. Demers R.Y., Tiwari A., Wei J., Weiss L.K., Severson R.K., and Montie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 92 9 (2001) 2309-2317
15. Mohile S.G., and Petrylak D.P. Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. Curr Oncol Rep 8 3 (2006) 213-220
16. Harlan S.R., Cooperberg M.R., Elkin E.P., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 170 5 (2003) 1804-1807
17. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 13 (2003) 981-989
18. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 17 (1999) 1591-1597
19. Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 20 4 (2006) 909-923
20. Joly F., Alibhai S.M., Galica J., et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 176 6 Pt 1 (2006) 2443-2447
21. Bylow K., Mohile S.G., Stadler W.M., and Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review. Cancer 110 12 (2007) 2604-2613
22. Mohile S.G., Bylow K., Dale W., et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109 4 (2007) 802-810
23. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 14 (2004) 2927-2941
24. Seidenfeld J., Samson D.J., Hasselblad V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132 7 (2000) 566-577
25. Bonzani R.A., Stricker H.J., Peabody J.O., and Menon M. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 160 6 Pt 2 (1998) 2446-2449
26. Seidenfeld J., Samson D.J., Aronson N., et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 4 (1999) I-x, 1-246, I1-36, passim
27. Murthy V., Norman A.R., Shahidi M., et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int 97 3 (2006) 476-479
28. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 2 (2002) 362-367
29. Bales G.T., and Chodak G.W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47 1A Suppl. (1996) 38-43 discussion 8-53
30. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 2 (2002) 361-376
31. Schmitt B., Bennett C., Seidenfeld J., Samson D., and Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2 (2000) CD001526
32. Schmitt B., Wilt T.J., Schellhammer P.F., et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57 4 (2001) 727-732
33. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355(9214):1491-8.
34. Alibhai S.M., Gogov S., and Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60 3 (2006) 201-215
35. Spetz A.C., Hammar M., Pettersson W., and Varenhorst E. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int 90 4 (2002) 476 author reply - 7
36. Schow D.A., Renfer L.G., Rozanski T.A., and Thompson I.M. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91 9 (1998) 855-857
37. Karling P., Hammar M., and Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152 4 (1994) 1170-1173
38. Holzbeierlein J.M. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 33 2 (2006) 181-190 vi
39. Spetz A.C., Zetterlund E.L., Varenhorst E., and Hammar M. Incidence and management of hot flashes in prostate cancer. J Support Oncol 1 4 (2003) 263-266 9-70, 72-3; discussion 7-8, 71-2
40. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 23 1 (2005) 56-64
41. Moyad M.A. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 59 4 Suppl. 1 (2002) 20-33
42. Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 2 Suppl. 1 (2003) 32-38
43. Frisk J, Spetz AC, Hjertberg H, Petersson B, Hammar M. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer-a prospective multicenter study with long-term follow-up. Eur Urol 2008, doi:10.1016/j.eururo.2008.02.002.
44. Filshie J., Bolton T., Browne D., and Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients-audit and treatment algorithm. Acupunct Med 23 4 (2005) 171-180
45. Kronenberg F., and Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 137 10 (2002) 805-813
46. Albertazzi P., Pansini F., Bonaccorsi G., Zanotti L., Forini E., and De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 91 1 (1998) 6-11
47. Pruthi S., Thompson S.L., Novotny P.J., et al. Pilot evaluation of flaxseed for the management of hot flashes. J Soc Integr Oncol 5 3 (2007) 106-112
48. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 11 (2005) 1338-1347
49. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 1 (2005) 37-46
50. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 331 6 (1994) 347-352
51. Sartor O., and Eastham J.A. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 92 4 (1999) 415-416
52. Tassinari D., Fochessati F., Panzini I., Poggi B., Sartori S., and Ravaioli A. Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia. J Pain Symptom Manage 25 5 (2003) 481-484
53. Langenstroer P., Kramer B., Cutting B., et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174 2 (2005) 642-645
54. Miller J.I., and Ahmann F.R. Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology 40 6 (1992) 499-502
55. Gerber G.S., Zagaja G.P., Ray P.S., and Rukstalis D.B. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55 1 (2000) 97-101
56. Kerwin J.P., Gordon P.R., and Senf J.H. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 14 5 (2007) 841-845
57. Grady D., Cohen B., Tice J., Kristof M., Olyaie A., and Sawaya G.F. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 109 4 (2007) 823-830
58. Roth A.J., and Scher H.I. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 7 2 (1998) 129-132
59. Loprinzi C.L., Pisansky T.M., Fonseca R., et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16 7 (1998) 2377-2381
60. Quella S.K., Loprinzi C.L., Sloan J., et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162 1 (1999) 98-102
61. Loprinzi C.L., Kugler J.W., Sloan J.A., et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 9247 (2000) 2059-2063
62. Pandya K.J., Morrow G.R., Roscoe J.A., et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366 9488 (2005) 818-824
63. Loprinzi C.L., Kugler J.W., Barton D.L., et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 25 3 (2007) 308-312
64. Strum S.B., McDermed J.E., Scholz M.C., Johnson H., and Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 6 (1997) 933-941
65. Chander S., Choo R., Danjoux C., et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62 3 (2005) 719-724
66. Asbell S.O., Leon S.A., Tester W.J., Brereton H.D., Ago C.T., and Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29 4 (1996) 243-248
67. Bennett C.L., Silver S.M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 8 (2008) 914-924
68. Guan X., and Chen L. Role of erythropoietin in cancer-related anaemia: a double-edged sword?. J Int Med Res 36 1 (2008) 1-8
69. Traish A.M., and Guay A.T. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3 3 (2006) 382-404 discussion-7
70. Morley J.E., Haren M.T., Kim M.J., Kevorkian R., and Perry III H.M. Testosterone, aging and quality of life. J Endocrinol Invest 28 3 Suppl. (2005) 76-80
71. Marumo K., Baba S., and Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 6 1 (1999) 19-23
72. Teloken P.E., Ohebshalom M., Mohideen N., and Mulhall J.P. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 178 6 (2007) 2521-2525
73. Miles C.L., Candy B., Jones L., Williams R., Tookman A., and King M. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 4 (2007) CD005540
74. Schover L.R., Fouladi R.T., Warneke C.L., et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 95 11 (2002) 2397-2407
75. Aucoin M.W., and Wassersug R.J. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients. Soc Sci Med 63 12 (2006) 3162-3173
76. Boehmer U., and Babayan R.K. Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partners. Cancer Invest 22 6 (2004) 840-848
77. Canada A.L., Neese L.E., Sui D., and Schover L.R. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 104 12 (2005) 2689-2700
78. Potosky A.L., Reeve B.B., Clegg L.X., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94 6 (2002) 430-437
79. Dale J., Jatsch W., Hughes N., Pearce A., and Meystre C. Information needs and prostate cancer: the development of a systematic means of identification. BJU Int 94 1 (2004) 63-69
80. Pirl W.F., Siegel G.I., Goode M.J., and Smith M.R. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11 6 (2002) 518-523
81. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166 4 (2006) 465-471
82. Penedo F.J., Molton I., Dahn J.R., et al. A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med 31 3 (2006) 261-270
83. Penedo F.J., Dahn J.R., Molton I., et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. Cancer 100 1 (2004) 192-200
84. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 4 (2002) 427-432
85. Green H.J., Pakenham K.I., Headley B.C., et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93 7 (2004) 975-979
86. Jenkins V.A., Bloomfield D.J., Shilling V.M., and Edginton T.L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96 1 (2005) 48-53
87. Almeida O.P., Waterreus A., Spry N., Flicker L., and Martins R.N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29 8 (2004) 1071-1081
88. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 5 (2003) 1808-1811
89. Salminen E., Portin R., Korpela J., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 89 6 (2003) 971-976
90. Salminen E.K., Portin R.I., Koskinen A., Helenius H., and Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 22 (2004) 7575-7582
91. Taxel P., Stevens M.C., Trahiotis M., Zimmerman J., and Kaplan R.F. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 52 2 (2004) 269-273
92. Beer T.M., Bland L.B., Bussiere J.R., et al. Testosterone loss and estradiol administration modify memory in men. J Urol. 175 1 (2006) 130-135
93. Rodin M.B., and Mohile S.G. A practical approach to geriatric assessment in oncology. J Clin Oncol 25 14 (2007) 1936-1944
94. Pfeiffer E. A Short Portable Mental Status Questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23 10 (1975) 433-441
95. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 24 (2006) 3979-3983
96. Smith M.R., Lee H., McGovern F., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008)
97. Yannucci J., Manola J., Garnick M.B., Bhat G., and Bubley G.J. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 176 2 (2006) 520-525
98. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 27 (2006) 4448-4456
99. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 20 (2007) 1516-1524
100. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 7 (2007) 1493-1500
101. Higano C.S. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat Clin Pract Urol 5 1 (2008) 24-34
102. Orsini L.S., Rousculp M.D., Long S.R., and Wang S. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16 4 (2005) 359-371
103. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 9156 (1999) 878-882
104. Riggs B.L., Khosla S., and Melton III L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23 3 (2002) 279-302
105. Smith M.R., Goode M., Zietman A.L., McGovern F.J., Lee H., and Finkelstein J.S. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22 13 (2004) 2546-2553
106. Morote J., Morin J.P., Orsola A., et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69 3 (2007) 500-504
107. Ryan C.W., Huo D., Stallings J.W., Davis R.L., Beer T.M., and McWhorter L.T. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70 1 (2007) 122-126
108. Smith M.R., Lee W.C., Brandman J., Wang Q., Botteman M., and Pashos C.L. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 31 (2005) 7897-7903
109. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 2 (2005) 154-164
110. Smith M.R., Boyce S.P., Moyneur E., Duh M.S., Raut M.K., and Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175 1 (2006) 136-139 discussion 9
111. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 2 (1997) 439-444
112. Melton III L.J., Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., and Zincke H. Fracture risk following bilateral orchiectomy. J Urol 169 5 (2003) 1747-1750
113. Diamond T.H., Higano C.S., Smith M.R., Guise T.A., and Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 5 (2004) 892-899
114. Gregg E.W., Cauley J.A., Seeley D.G., Ensrud K.E., and Bauer D.C. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 129 2 (1998) 81-88
115. Segal R.J., Reid R.D., Courneya K.S., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21 9 (2003) 1653-1659
116. Bylow K., Dale W., Mustian K., et al. Falls and physical performance deficits in older prostate cancer patients on androgen deprivation therapy. Urology 72 2 (2008) 422-427
117. Tinetti M.E. Clinical practice. Preventing falls in elderly persons. N Engl J Med 348 1 (2003) 42-49
118. Swanenburg J., de Bruin E.D., Stauffacher M., Mulder T., and Uebelhart D. Effects of exercise and nutrition on postural balance and risk of falling in elderly people with decreased bone mineral density: randomized controlled trial pilot study. Clin Rehabil 21 6 (2007) 523-534
119. Lui P.P., Qin L., and Chan K.M. Tai Chi Chuan exercises in enhancing bone mineral density in active seniors. Clin Sports Med 27 1 (2008) 75-86 viii
120. Dawson-Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337 10 (1997) 670-676
121. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 13 (2001) 948-955
122. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 6 (2003) 2008-2012
123. Ryan C.W., Huo D., Demers L.M., Beer T.M., and Lacerna L.V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176 3 (2006) 972-978 discussion 8
124. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 9 (2007) 1038-1042
125. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 9 (2000) 604-610
126. Greenspan S.L., Nelson J.B., Trump D.L., and Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146 6 (2007) 416-424
127. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 18 (2007) 1809-1822
128. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 8 (2003) 1735-1744
129. von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 10 Suppl. 1 (2005) 19-24
130. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89 8 (2004) 3841-3846
131. Naeim A., and Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology (Williston Park) 15 12 (2001) 1567-1577 80; discussion 81, 86, 91
132. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103 2 (2005) 237-241
133. Yee E.F., White R.E., Murata G.H., Handanos C., and Hoffman R.M. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 22 9 (2007) 1305-1310
134. Smith M.R. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol 172 5 Pt 2 (2004) S52-S56
135. Smith M.R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63 4 (2004) 742-745
136. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 3 (2001) M146-M156
137. Carmeli E., Coleman R., and Reznick A.Z. The biochemistry of aging muscle. Exp Gerontol 37 4 (2002) 477-489
138. Baumgartner R.N., Koehler K.M., Gallagher D., et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147 8 (1998) 755-763
139. Gallagher D., Ruts E., Visser M., et al. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 279 2 (2000) E366-E375
140. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 6 (2002) 2361-2367 discussion 7
141. Boxer R.S., Kenny A.M., Dowsett R., and Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 8 3-4 (2005) 207-212
142. Lindle R.S., Metter E.J., Lynch N.A., et al. Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr. J Appl Physiol 83 5 (1997) 1581-1587
143. Fiatarone M.A., Marks E.C., Ryan N.D., Meredith C.N., Lipsitz L.A., and Evans W.J. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 263 22 (1990) 3029-3034
144. Frontera W.R., Hughes V.A., Lutz K.J., and Evans W.J. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol 71 2 (1991) 644-650
145. Basaria S., Lieb II J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56 6 (2002) 779-786
146. Clay C.A., Perera S., Wagner J.M., Miller M.E., Nelson J.B., and Greenspan S.L. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 87 10 (2007) 1325-1333
147. Bylow K., Dale W., Mustian K., et al. Falls and physical performance deficits in older prostate cancer patients on androgen deprivation therapy. Urology 72 2 (2008) 422-427
148. Fortinsky R.H., Iannuzzi-Sucich M., Baker D.I., et al. Fall-risk assessment and management in clinical practice: views from healthcare providers. J Am Geriatr Soc 52 9 (2004) 1522-1526
149. McClure R., Turner C., Peel N., Spinks A., Eakin E., and Hughes K. Population-based interventions for the prevention of fall-related injuries in older people. Cochrane Database Syst Rev 1 (2005) CD004441
150. Pynoos J., Rose D., Rubenstein L., Choi I.H., and Sabata D. Evidence-based interventions in fall prevention. Home Health Care Serv Q 25 1-2 (2006) 55-73
151. Galvao D.A., Nosaka K., Taaffe D.R., et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38 12 (2006) 2045-2052
152. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 17 (2001) 3750-3757
153. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20 2 (2002) 557-566
154. Fowler Jr. F.J., McNaughton Collins M., Walker Corkery E., Elliott D.B., and Barry M.J. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95 2 (2002) 287-295
155. Dacal K., Sereika S.M., and Greenspan S.L. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54 1 (2006) 85-90
156. Lubeck D.P., Litwin M.S., Henning J.M., Stoddard M.L., Flanders S.C., and Carroll P.R. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology 53 1 (1999) 180-186
157. Lubeck D.P., Grossfeld G.D., and Carroll P.R. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 58 2 Suppl. 1 (2001) 94-100
158. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 6 (2000) 1743-1746
159. van Andel G., and Kurth K.H. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 44 2 (2003) 209-214
160. Arredondo S.A., Latini D.M., Sadetsky N., et al. Quality of life for men receiving a second treatment for prostate cancer. J Urol 177 1 (2007) 273-278 discussion 8-9
161. Litwin M.S., Shpall A.I., Dorey F., and Nguyen T.H. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21 4 (1998) 327-332
162. Moinpour C.M., Savage M.J., Troxel A., et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90 20 (1998) 1537-1544
163. Litwin M.S. Health related quality of life in older men without prostate cancer. J Urol 161 4 (1999) 1180-1184
164. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 12 (2008) 1250-1261
165. Inouye S.K., Peduzzi P.N., Robison J.T., Hughes J.S., Horwitz R.I., and Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 279 15 (1998) 1187-1193
166. Fried T.R., and Mor V. Frailty and hospitalization of long-term stay nursing home residents. J Am Geriatr Soc 45 3 (1997) 265-269
167. Stuck A.E., Siu A.L., Wieland G.D., Adams J., and Rubenstein L.Z. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342 8878 (1993) 1032-1036
168. Ettinger W.H., Davis M.A., Neuhaus J.M., and Mallon K.P. Long-term physical functioning in persons with knee osteoarthritis from NHANES. I. Effects of comorbid medical conditions. J Clin Epidemiol 47 7 (1994) 809-815
169. Fried L.P., Bandeen-Roche K., Kasper J.D., and Guralnik J.M. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 52 1 (1999) 27-37
170. Luchi R.J., Gammack J.K., Narcisse III V.J., and Storey Jr. C.P. Standards of care in geriatric practice. Annu Rev Med 54 (2003) 185-196
171. Naeim A., Hurria A., Leake B., and Maly R.C. Do age and ethnicity predict breast cancer treatment received? A cross-sectional urban population based study Breast cancer treatment: Age and ethnicity. Crit Rev Oncol Hematol (2006)
172. Koroukian S.M., Murray P., and Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 24 15 (2006) 2304-2310
173. Flood K.L., Carroll M.B., Le C.V., Ball L., Esker D.A., and Carr D.B. Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit. J Clin Oncol 24 15 (2006) 2298-2303
174. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 3 (2005) 241-252
175. Carreca I., Balducci L., and Extermann M. Cancer in the older person. Cancer Treat Rev 31 5 (2005) 380-402
176. Lichtman S.M. Guidelines for the treatment of elderly cancer patients. Cancer Control 10 6 (2003) 445-453
177. Katz S., Ford A.B., Moskowitz R.W., Jackson B.A., and Jaffe M.W. Studies of illness in the aged. The Index of ADL: a standardized measure of biological and psychosocial function. JAMA 185 (1963) 914-919
178. Lawton M.P. Scales to measure competence in everyday activities. Psychopharmacol Bull 24 4 (1988) 609-614
179. Guralnik J.M., Ferrucci L., Simonsick E.M., Salive M.E., and Wallace R.B. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 332 9 (1995) 556-561
180. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
181. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 6 (1992) 473-483
182. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., and Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289 13 (2003) 1652-1658
183. Fillenbaum G., Heyman A., Williams K., Prosnitz B., and Burchett B. Sensitivity and specificity of standardized screens of cognitive impairment and dementia among elderly black and white community residents. J Clin Epidemiol 43 7 (1990) 651-660
184. Guralnik J.M., Simonsick E.M., Ferrucci L., et al. A Short Physical Performance Battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49 2 (1994) M85-M94
185. Hays R.D., Sherbourne C.D., and Mazel R.M. The RAND 36-Item Health Survey 1.0. Health Econ 2 3 (1993) 217-227
186. Saliba D., Elliott M., Rubenstein L.Z., et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49 12 (2001) 1691-1699
187. Szulc P., Claustrat B., Marchand F., and Delmas P.D. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 88 11 (2003) 5240-5247
188. Balducci L., and Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol 33 2 (2000) 143-148
189. Basso U., Tonti S., Bassi C., et al. Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. Crit Rev Oncol Hematol (2008)